​Helsinki Biobank and Fimmic Introduce a Unique One Access Service for Biomedical Research

HELSINKI - October 25, 2018 - Helsinki Biobank and medical AI software company Fimmic announce a collaboration by presenting a unique one access service concept. The new service combines Helsinki Biobank´s large collection of pathology samples and world-class digital services with state-of-the art deep learning AI -based image analysis solutions from Fimmic.

"We believe that together we can offer something extraordinary for the research and drug development community", says Kaisa Helminen, Fimmic CEO. "Helsinki Biobank has a significant collection of tissue samples with excellent, comprehensive patient records. We at Fimmic have developed a unique cloud-based software platform, Aiforia®, where the analysis of tissue sample images can be fully automated. The analysis is based on deep learning AI technology, which enables automated identification, quantification and classification of complex or rare target features, e.g. malignant tumors. This opens up enormous possibilities for new discoveries from biological samples."

"Together we are in a unique position to combine state-of-the-art technologies and medical research expertise with biobanking, which is more and more about turning the samples into data", explains Kimmo Pitkänen, Director of Helsinki Biobank. "Our new one access service really brings biodata banking to practice. Instead of giving out only a physical sample, Helsinki Biobank gives the researcher the sample in a digitalized form combined the deep clinical and biological data from the hospital data lake. Now, together with Fimmic, we can combine it with digital analyses capabilities. This creates new exciting possibilities for medical research."

"Fast and easy access to intelligent image analysis tools which facilitate high-throughput analysis of tissue samples holds the potential for more efficient drug discovery and drug development. Together with Helsinki Biobank, we can offer full digital pathology service for the research and pharma community, and thus facilitate and speed up their research endeavours", Helminen summarizes.